Neurodegenerative Disease Market Size, Share, Trends, Growth Outlook

Neurodegenerative Disease Market is estimated to increase at a Compounded Annual Growth Rate of 7.5% CAGR over the forecast period from 2024 to 2030

The Neurodegenerative Disease Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Indication (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, Others), By Drug (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Others).

An Introduction to Neurodegenerative Disease Market in 2024

In 2024, the market for neurodegenerative disease therapeutics continues to address the urgent need for effective treatments for conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. Neurodegenerative diseases are characterized by the progressive degeneration and loss of neurons in the central nervous system, leading to cognitive decline, motor dysfunction, and ultimately, disability and death. With an aging population and the increasing prevalence of neurodegenerative disorders, there is a growing demand for disease-modifying therapies that can slow or halt disease progression and improve quality of life for affected individuals. Moreover, the market is influenced by trends such as the development of disease-specific biomarkers, genetic therapies, and neuroprotective agents targeting protein aggregation, inflammation, oxidative stress, and synaptic dysfunction. Additionally, ongoing research focuses on unraveling the underlying mechanisms of neurodegeneration, identifying novel drug targets, and exploring innovative therapeutic approaches such as gene editing, stem cell transplantation, and neuroregenerative strategies, reflecting the continuous dedication to advancing neurodegenerative disease research and finding effective treatments for these devastating conditions.

Market Trend: Increasing Focus on Disease-modifying Therapies and Precision Medicine

A prominent market trend in the neurodegenerative disease market is the increasing focus on the development of disease-modifying therapies and precision medicine approaches. Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS), pose significant challenges to patients, caregivers, and healthcare systems worldwide due to their progressive nature and limited treatment options. In recent years, there has been a shift in research and drug development towards targeting the underlying molecular mechanisms and pathological processes involved in neurodegeneration, to slow or halt disease progression. Additionally, advancements in precision medicine, including genomics, proteomics, and biomarker identification, are enabling more tailored and individualized approaches to diagnosis, prognosis, and treatment selection for patients with neurodegenerative diseases. This trend toward disease-modifying therapies and precision medicine offers new hope for patients and caregivers, driving investment and innovation in the neurodegenerative disease market.

Market Driver: Aging Population and Growing Disease Burden

A significant driver fueling the growth of the neurodegenerative disease market is the aging population and the increasing burden of age-related neurological disorders. As the global population continues to age, particularly in developed countries, there's a corresponding rise in the prevalence of neurodegenerative diseases, which are more common among older adults. Age-related changes in cellular function, oxidative stress, and protein misfolding contribute to the pathogenesis of neurodegenerative diseases, leading to progressive neuronal damage and functional decline. The growing disease burden of neurodegenerative disorders, coupled with the lack of effective disease-modifying treatments, underscores the urgent need for innovative therapeutic interventions and supportive care strategies to address the complex needs of patients with neurodegenerative diseases and their caregivers. This demographic trend drives demand for research funding, clinical trials, and healthcare services aimed at improving early detection, diagnosis, and management of neurodegenerative diseases, driving growth in the neurodegenerative disease market.

Market Opportunity: Development of Disease-modifying Therapies and Biomarkers

An intriguing opportunity within the neurodegenerative disease market lies in the development of disease-modifying therapies and biomarkers that can accurately diagnose, monitor, and predict disease progression in patients with neurodegenerative disorders. While symptomatic treatments can provide temporary relief of symptoms, there is a critical need for interventions that can alter the underlying disease processes and delay disease progression. By targeting specific molecular pathways, protein aggregates, or pathological mechanisms implicated in neurodegeneration, pharmaceutical companies and biotechnology firms can develop novel therapeutics that slow or halt disease progression, offering new hope for patients with neurodegenerative diseases. Additionally, there's potential for the discovery and validation of biomarkers, such as genetic markers, imaging techniques, or fluid-based assays, that can aid in early diagnosis, prognostication, and treatment response monitoring in neurodegenerative diseases. By investing in research and development efforts aimed at advancing disease-modifying therapies and biomarker-driven approaches, companies can address critical unmet needs in the neurodegenerative disease market, improve patient outcomes, and contribute to the advancement of neurological science and medicine.

Neurodegenerative Disease Market Share Analysis: Immunomodulatory Drugs for Multiple Sclerosis

In the Neurodegenerative Disease Market, the segment experiencing rapid growth is Immunomodulatory Drugs for Multiple Sclerosis. Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by inflammation and damage to the myelin sheath surrounding nerve fibers in the central nervous system. Immunomodulatory drugs, such as interferons, glatiramer acetate, and sphingosine-1-phosphate receptor modulators, are the cornerstone of treatment for MS. These drugs work by modulating the immune response to reduce inflammation and slow disease progression in patients with relapsing forms of MS. With advancements in understanding the pathophysiology of MS and the development of novel immunomodulatory therapies, there has been a significant expansion in the treatment armamentarium for MS. Additionally, the increasing prevalence of MS worldwide and the growing adoption of disease-modifying therapies contribute to the rapid growth of immunomodulatory drugs in the MS market segment. As healthcare providers prioritize early diagnosis and effective management of MS to improve patient outcomes and quality of life, the market for immunomodulatory drugs for MS is expected to witness significant growth in the neurodegenerative disease market.

Neurodegenerative Disease Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbVie Inc, Amneal Pharmaceuticals Inc, Biogen Inc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, UCB S.A.

Neurodegenerative Disease Market Segmentation

By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Neurodegenerative Disease Market Companies

AbbVie Inc
Amneal Pharmaceuticals Inc
Biogen Inc
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Teva Pharmaceutical Industries Ltd
UCB S.A.

Reasons to Buy the Neurodegenerative Disease Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Neurodegenerative Disease Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Neurodegenerative Disease Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Neurodegenerative Disease Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Neurodegenerative Disease Market Size Outlook, $ Million, 2021 to 2030
3.2 Neurodegenerative Disease Market Outlook by Type, $ Million, 2021 to 2030
3.3 Neurodegenerative Disease Market Outlook by Product, $ Million, 2021 to 2030
3.4 Neurodegenerative Disease Market Outlook by Application, $ Million, 2021 to 2030
3.5 Neurodegenerative Disease Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Neurodegenerative Disease Industry
4.2 Key Market Trends in Neurodegenerative Disease Industry
4.3 Potential Opportunities in Neurodegenerative Disease Industry
4.4 Key Challenges in Neurodegenerative Disease Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Neurodegenerative Disease Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Neurodegenerative Disease Market Outlook by Segments
7.1 Neurodegenerative Disease Market Outlook by Segments, $ Million, 2021- 2030
By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others

8 North America Neurodegenerative Disease Market Analysis and Outlook To 2030
8.1 Introduction to North America Neurodegenerative Disease Markets in 2024
8.2 North America Neurodegenerative Disease Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Neurodegenerative Disease Market size Outlook by Segments, 2021-2030
By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others

9 Europe Neurodegenerative Disease Market Analysis and Outlook To 2030
9.1 Introduction to Europe Neurodegenerative Disease Markets in 2024
9.2 Europe Neurodegenerative Disease Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Neurodegenerative Disease Market Size Outlook by Segments, 2021-2030
By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others

10 Asia Pacific Neurodegenerative Disease Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Neurodegenerative Disease Markets in 2024
10.2 Asia Pacific Neurodegenerative Disease Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Neurodegenerative Disease Market size Outlook by Segments, 2021-2030
By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others

11 South America Neurodegenerative Disease Market Analysis and Outlook To 2030
11.1 Introduction to South America Neurodegenerative Disease Markets in 2024
11.2 South America Neurodegenerative Disease Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Neurodegenerative Disease Market size Outlook by Segments, 2021-2030
By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others
12 Middle East and Africa Neurodegenerative Disease Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Neurodegenerative Disease Markets in 2024
12.2 Middle East and Africa Neurodegenerative Disease Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Neurodegenerative Disease Market size Outlook by Segments, 2021-2030
By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Amneal Pharmaceuticals Inc
Biogen Inc
Boehringer Ingelheim International GmbH
F. Hoffmann-La Roche Ltd
Johnson & Johnson
Merck & Co. Inc
Novartis AG
Pfizer Inc
Sanofi SA
Teva Pharmaceutical Industries Ltd
UCB S.A.

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Indication
Parkinson's Disease
Alzheimer's Disease
Multiple Sclerosis
Huntington Disease
Others
By Drug
N-methyl-D-aspartate Receptor Antagonists
Cholinesterase Inhibitors
Dopamine Agonists
Immunomodulatory Drugs
Others
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)